Laying birds:
The safety of the veterinary medicinal product has been demonstrated when administered during lay. The efficacy of the veterinary medicinal product has not been demonstrated when administered during lay. A decision to use this vaccine during lay should be made on a case by case basis.
Vaccinate only healthy animals.
The vaccine virus is capable of spreading to in contact birds for a minimum of 14 days after vaccination and appropriate care should be taken to separate vaccinated from non-vaccinated chickens. Precautionary measures should be taken to prevent spreading to wildlife. Cleaning and disinfection of the premises after vaccination is advisable.
This vaccine should only be used after it has been established that the QX-like IBV variant strain is epidemiologically relevant. It is important to avoid introduction of the IB QX vaccine virus into premises in which the wild type strain is not present. The IB QX vaccine should only be applied in hatcheries if adequate controls are in place to avoid the spread of the vaccine virus to birds that will be transported to non-IB QX exposed flocks.
The vaccine has been demonstrated to provide protection against QX-like variant. The protection against other circulating IB strains has not been investigated.
When vaccination is planned in future layers or breeders younger than 7 days, the parent flock should be vaccinated with an IB vaccine to ensure progeny with MDAs against IBV.
All chickens on the site should be vaccinated at the same time.
As there is a small range between the efficacious vaccine dose and a non-efficacious dose, take care to administer the right dose.
Chickens:
Very rare (< 1 animal / 10,000 animals treated, including isolated reports) | respiratory signs1 |
1Generally mild and last a few days.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the packaging leaflet for respective contact details.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Do not mix with any other veterinary medicinal product.
Withdrawal period
Zero days
User warnings
Care should be taken when reconstituting and administering the vaccine. Wear a suitable respiratory mask and eye protection to avoid direct contact with the aerosolized vaccine. Wash and disinfect hands after use.